Concurrent B-Cell Follicular and Refractory CD30+ Large Cell Transformation of Mycosis Fungoides Responsive to Rituximab and Brentuximab Vedotin

Journal of Blood Disorders & Transfusion
doi 10.4172/2155-9864.1000259
Full Text
Abstract

Available in full text

Date
Authors
Publisher

OMICS Publishing Group

Related search

Oral Mycosis Fungoides With CD30+ Large Cell Transformation Successfully Treated With Brentuximab Vedotin

JAAD Case Reports
Dermatology
2019English

A Case of Refractory Sézary Syndrome With Large-Cell Transformation Responsive to Brentuximab Vedotin

JAMA Dermatology
DermatologyMedicine
2014English

Brentuximab as a Treatment for CD30+Mycosis Fungoides and Sézary Syndrome

JAMA Dermatology
DermatologyMedicine
2015English

Response to Brentuximab Vedotin by Cd30 Expression: Results From Five Trials in Ptcl, Ctcl, and B-Cell Lymphomas

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

A Cost-Effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Journal of Health Economics and Outcomes Research
2016English

Targeted Drug Brentuximab Vedotin for Treatment of Relapsed or Refractory Cd30-Positive Hodgkin’s Lymphoma

Malignant tumours
2017English

Brentuximab Vedotin for Relapsed or Refractory CD30+ Hodgkin Lymphoma: A Multicenter Analysis From Asia

OncoTargets and Therapy
OncologyPharmacology
2014English

CD30 Expression and Proliferative Fraction in Nontransformed Mycosis Fungoides

American Journal of Surgical Pathology
AnatomyForensic MedicinePathologySurgery
2009English

Cutaneous T-Cell Lymphoma (Mycosis Fungoides)

Medical Journal Armed Forces India
Medicine
2007English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy